Clinical Trials Logo

Castration-Resistant Prostate Cancer clinical trials

View clinical trials related to Castration-Resistant Prostate Cancer.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT06033001 Available - Clinical trials for Castration-Resistant Prostatic Cancer

Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this program is to provide access to [Lu-177]-PNT2002 to patients who have been diagnosed with prostate-specific membrane antigen (PMSA)-positive castration-resistant prostate cancer (mCRPC). Patients must have received at least 1 prior androgen pathway inhibitor (ARPI) and cannot be treated by currently available drugs or clinical trials. In this program participants will be administered [Lu-177]-PNT2002 intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment. During treatment, participants will be monitored with routine laboratory tests such as: - Hematology blood tests - Clinical Chemistry blood tests - Testosterone/Prostate Antigen levels blood test - Vital signs - Imaging - ECG